Associated Papers
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Ferng TT et al.
Molecular Cancer Therapeutics, 2022
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
Nishida Y et al.
Leukemia, 2021
The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.
Al-Subaie AM et al.
International Journal of Molecular Sciences, 2021
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Rummelt C et al.
Leukemia, 2021
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC et al.
Blood Advances, 2020
High incidence of FLT3 mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage.
Borowczyk M et al.
Therapeutic Advances in Medical Oncology, 2020
Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies.
Zhou J et al.
World Journal of Clinical Oncology, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.
Jiang X et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Molecular targeting in acute myeloid leukemia.
Lim SH et al.
Journal of Translational Medicine, 2017
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Nguyen B et al.
Oncotarget, 2017
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia.
Yue Y et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2016
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.
Smith CC et al.
Leukemia, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Smith CC et al.
Cancer Discovery, 2015
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.
Chen W et al.
Molecular Cancer, 2010
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W et al.
Journal of the National Cancer Institute, 2008
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Tickenbrock L et al.
Expert Opinion on Emerging Drugs, 2006